by Sean Hughes | Mar 1, 2018 | Briefings, US & International
Europe The Enlarged Board of Appeal in G 02/08 clarified that second medical use claims to new and inventive dosage regimes are patentable, even where the substance or composition, and the disease to be treated, are the same as in the prior art. Nevertheless, the...
by Alex Bajjon | Nov 1, 2017 | US & International
The Case In 2016, Fresenius requested a declaration of non-infringement in Italy for its pemetrexed diacid product in respect of Lilly’s European patent EP1313508. Lilly’s patent was amended during prosecution to specify in claim 1 that pemetrexed disodium...
by Juliette Boynton | Aug 1, 2017 | US & International
In 2010 Apotex started to sell a generic version of this drug and AstraZeneca brought an action against Apotex for patent infringement. In response Apotex counter-claimed to have the patent declared invalid. In the first instance decision the Judge held that the...
by Sean Hughes | Feb 1, 2017 | US & International
Background The Polish Regional Court had awarded damages for a much lower sum than that which was claimed by the claimant, noting that an award of punitive damages in respect of an infringed IP right would likely contravene Article 13 of the Enforcement Directive,...
by Alex Bajjon | Feb 1, 2017 | US & International
Criteria – Three-Step Test In order for the disputed domain names to be either cancelled or transferred, a panellist/panel must find that the following three conditions are met: The domain name registered by the domain name registrant is identical or confusingly...
by Sean Hughes | Nov 1, 2016 | US & International
Introduction The Cancer Immunotherapy Pilot Program, also known as “Patents 4 Patients”, makes certain US patent applications relating to cancer immunotherapy eligible for special status and examination with the goal of completing prosecution within 12...
Recent Comments